ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron® Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. Key HighlightsIn December 2025, the Company announced the results of an interim analysis of the Halneuron® Phase 2b trial. The independent statistical review committee...

Fourth quarter of 2025 revenue increased 70.2% year-over-year to $12.0 million, with record quarterly gross margin of 58.5% Net income from continuing operations of $2.0 million for 2025 fourth quarter Positive defense and commercial market demand is expected to support another strong year of revenue growth in 2026 ESCONDIDO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML), autonomy and sensor processing at the edge, reported results for the fourth quarter ended December 31, 2025. Fourth quarter and twelve-month comparisons are to the same year-ago periods unless otherwise noted. On December 30, 2025, the Company closed a definitive agreement to sell...

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the fourth quarter and full year ended December 31, 2025. “We are entering 2026 with a pivotal transaction that establishes...

U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended December 31, 2025, and provided a corporate update. Highlights include recent U.S. and European patent developments, the closing of a $12 million private investment, and the acceptance of a New Drug Application (NDA) for its lead candidate, CTx-1301 (dexmethylphenidate HCl). Cingulate CEO Shane J. Schaffer stated, “Cingulate delivered on key inflection points throughout 2025...

MAYFIELD VILLAGE, OHIO, March 18, 2026 (GLOBE NEWSWIRE) — The Progressive Corporation (NYSE:PGR) today reported the following results for the month ended February 28, 2026:  February(millions, except per share amounts and ratios; unaudited)   2026       2025     ChangeNet premiums written $ 6,995     $ 6,684     5   %Net premiums earned $ 6,528     $ 6,036     8   %Net income $ 943     $ 928     2   %Per share available to common shareholders $ 1.61     $ 1.58     2   %Total pretax net realized gains (losses) on securities $ (5 )   $ (110 )   (95 ) %Combined ratio   85.7       82.6     3.1   pts.Average diluted equivalent common shares   586.8       587.6     0   %  February 28,(thousands; unaudited) 2026   2025   % ChangePolicies in Force          Personal Lines          Agency – auto 10,959   9,950   10Direct...

BEIJING, March 18, 2026 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HKEX: 2076), a leading online recruitment platform in China, today announced its unaudited financial results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 HighlightsTotal paid enterprise customers1 in the twelve months ended December 31, 2025 were 6.8 million, an increase of 11.5% from 6.1 million in the twelve months ended December 31, 2024. Average monthly active users (MAU)2 for the fourth quarter of 2025 were 58.0 million, an increase of 10.1% from 52.7 million for the same quarter of 2024. Average MAU for the full year of 2025 were 60.7 million, an increase of 14.5% from 53.0 million for the full year of 2024.Revenues for the fourth quarter of 2025 were RMB2,078.5 million (US$297.2...

AUSTIN, Texas, March 18, 2026 (GLOBE NEWSWIRE) — SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, today announced financial results for its fiscal fourth quarter and full year ended January 31, 2026. The company’s earnings release and presentation can be accessed on the quarterly results section of SailPoint’s investor relations website. SailPoint will host a conference call today at 8:30 a.m. Eastern Time to discuss the results and outlook, which is accessible here. About SailPoint At SailPoint (Nasdaq: SAIL), we believe enterprise security must start with identity at the foundation. Today’s enterprise runs on a diverse workforce of not just human but also digital identities—and securing them all is critical. Through the lens of identity, SailPoint empowers organizations to seamlessly manage and secure...

A total of 12,858 hotels or 1,264,419 hotel rooms in operation as of December 31, 2025. Hotel turnover1 increased 18.4% year-over-year to RMB28.1 billion in the fourth quarter of 2025 and increased 16.4% year-over-year for the full year of 2025. Excluding Steigenberger Hotels GmbH and its subsidiaries (“DH”, or “Legacy-DH”), hotel turnover from the Legacy-Huazhu2 segment increased 18.9% year-over-year in the fourth quarter of 2025 and increased 17.2% year-over-year for the full year of 2025. Hotel turnover from the Legacy-DH segment increased 13.7% year-over-year in the fourth quarter of 2025 and increased 8.5% year-over-year for the full year of 2025. Revenue increased 8.3% year-over-year to RMB6.5 billion (US$933 million)3 in the fourth quarter of 2025, surpassing the revenue guidance previously announced of a 2% to 6% increase compared...

Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full year 2024 Business development: Added 22 assets to portfolio, including five programs in Phase 2 or Phase 3 development Stock buyback program: Repurchased and retired 648,048 shares for an aggregate of $16.0 million Company acquisitions: Completed seven acquisitions, accumulating $11.7 million of non-dilutive capital1, economic interests of approximately 25% in up to $1.1 billion of milestones and low to mid-single digit royalties from eight partnered programs Key 2026 pipeline events: • Phase 2b data from volixibat in PSC in Q2 and Phase 3 data from ersodetug in tumor HI in 2H • Potential for EMA decisions on OJEMDA™...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures and an open-label, proof-of-concept study Expanding OV329 development to complementary indications in tuberous sclerosis complex seizures and infantile spasms, supported by a $60.0 million private placement OV4071, a first-in-class, oral KCC2 direct activator, received Human Research Ethics Committee approval and acknowledgement of its Clinical Trial Notification from the Australian Therapeutic Goods Administration, triggering a 30-day exercise period for the Company’s outstanding Series A Warrants Company to host KCC2-focused R&D Day on April 14, 2026 $90.4 million in cash, cash equivalents and marketable securities...